MDNA News and Press, Medicenna Therapeutics Corp. From 01/31/22

TORONTO and HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the formation of its Scientific Advisory Board (SAB) comprised o...

-- MDNA11 demonstrates a 30-fold increase in affinity for IL-2 receptor beta without binding to IL-2 receptor alpha when compared to recombinant human IL-2 -- MDNA11 was well-tolerated and induced durable proliferation and expansion of anti-cancer immune cells with limited stimu...

TORONTO and HOUSTON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Mann Muhsin has resigned as Chief Medical Officer of the Co...

TORONTO and HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that company management will be participating in the follow...

-- Peak CD8 + T cell (anti-tumor) / Treg (pro-tumor) ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial’s first two dose escalation cohorts -- MDNA11-induced increases in CD8 + T and NK cells compare favorably to competing I...

-- ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States -- Preliminary update on safety and PK/PD data expected by year-end 2021 -- Initial efficacy data update expected in m...

TORONTO and HOUSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that John H. Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria W...

Gainers: Kezar Life Sciences KZR +36%, Progenity (NASDAQ:PROG) +28%, GeoVax Labs GOVX +15%, Medicenna Therapeutics (NASDAQ:MDNA) +15%, Amarin AMRN +10%. Losers: Talkspace TALK -37%, OptiNose OPTN -34%, Molecular Partners MOLN&#x...

Creative Realities (NASDAQ:CREX) +91% industry merger creates powerful new digital signage leader EyePoint Pharmaceuticals EYPT +36% reports positive EYP-1901 data for treatment of wet AMD Bit Brother (NASDAQ:BTB) +20%. Oxbridge Re Holdings OXBR +15% on Q3 earnings. Cue Biophar...

Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna’s candidate for treating rGBM, MDNA55, has shown promising efficacy and safety data in its recently concluded phase II trial. MDNA11, an IL-2 s...